R&D/Clinical Trials

Pharma companies may benefit from meeting challenges and embracing small molecule drug discovery.

Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.

Has data science finally reached a level playing field with all of the science data being uncovered in the make, test, decide innovation cycle?

Kobel discusses taking a company public during a challenging time in the market.

Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.

As director of corporate strategy for Novartis, Kamenska defines direction for the company’s overall enterprise. Here, she discusses how the pandemic and recent market events are shaping these strategies.

Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.

Industry must continue research and development to combat the pandemic.

Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).

Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.

Survey taken by pharma and CRO executives evaluates attributes of large datasets.

Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.

Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.

Pharm Exec speaks with Ambrogio about the struggles the industry faces in regard to developing cures for rare cancers, and how Bayer is using precision medicine to meet these challenges.

Pharm Exec speaks with Adams about how his company developed a new medicine designed to meet migraine patients’ needs.

Industry has shown it can overcome challenges en route to creating new therapies.

New mediums of technology must be utilized correctly to reap full benefits.

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.

Foster talks to Pharm Exec about why liver disease is on the rise, and Hepion’s new therapy, rencofilstat, in development to treat it.

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

It takes flexibility and adaptability to switch a company’s focus. Here, Alkermes’ Chief Operating Officer Blair Jackson discusses how his team pivoted from developing CNS to oncology therapies and the skills it required.

Rush shares his thoughts on how advanced analytics are making their mark on the pharma industry.